Skip to content

Adaptive Biotechnologies ADPT Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$49.64M+16.5%-$59.46M+25.3%-$79.6M+34.3%-$121.24M+14.6%-$141.89M+11.1%
$15.24M-5.5%$16.13M-1.5%$16.39M-1.1%$16.57M-2.9%$17.07M-2.7%
$51.26M-0.4%$51.48M-0.2%$51.6M-0.5%$51.86M+0.8%$51.46M-4.0%
-$29.09M+39.4%-$48.04M+20.6%-$60.53M+24.8%-$80.47M+5.7%-$85.34M+10.4%
$2.5M-15.6%$2.96M+23.1%$2.4M+2.8%$2.34M-31.5%$3.41M-6.9%
$68.32M+21.3%$56.33M-4.3%$58.86M-24.3%
$32.45M+6.7%$30.4M+243%$8.87M+22.7%$7.23M+28.0%$5.65M+2,244%
$26.93M+20.4%$22.37M
-$30.95M+38.5%-$50.36M+20.0%-$62.94M+24.0%-$82.81M+6.7%-$88.76M+10.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Adaptive Biotechnologies generate?
Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.
What is Adaptive Biotechnologies's free cash flow?
After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.
Where does Adaptive Biotechnologies's cash flow data come from?
Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.